Systemic and Splanchnic Lipopolysaccharide and Endothelin-1 Plasma Levels in Liver Cirrhosis before and after Transjugular Intrahepatic Portosystemic Shunt by Jiaxiang Meng, Qing Wang, Kai Liu, Shuofei Yang, Xinxin Fan, Baochen Liu, Changsheng He, Xingjiang Wu

Get full text

Interleukin 15‐Presenting Nanovesicles with Doxorubicin‐Loaded Ferritin Cores for Cancer Immunochemotherapy by Yihui Zhai, Wen Zhang, Jinming Wang, Ying Kong, Rong Rong, Tianqun Lang, Chao Zheng, Yanke Wang, Yang Yu, Helen He Zhu, Ying Cai, Pengcheng Zhang, Yaping Li

Get full text

Molecular profiling and detection methods of microRNA in cancer research by Nurul-Syakima Ab Mutalib, Imilia Ismail, Hooi-Leng Ser

“…Acting like a “double-edge” sword, miRNAs can control and/or act as tumor suppressor genes and oncogenes, thus any unwanted alterations in their expression would bring upon disastrous effects on the host. …”
Get full text

Cytogenomic Characterization of Giant Ring or Rod Marker Chromosome in Four Cases of Well-Differentiated and Dedifferentiated Liposarcoma by Hongyan Chai, Fang Xu, Autumn DiAdamo, Brittany Grommisch, Huanzhi Mao, Peining Li

“…The levels of amplification for oncogenes OS9, CDK4, HMGA2, NUP107, MDM2, YEATS4, and FRS2 at the core segment or other SCNAs should be characterized to facilitate pathologic correlation and prognostic prediction. …”
Get full text

Belzutifan for the treatment of renal cell carcinoma by Xiancheng Wu, David Lazris, Risa Wong, Scott S. Tykodi

“…By inhibiting the HIF-2α transcription factor, belzutifan prevents HIF-2α from dimerizing with HIF-1β, thereby preventing the transcription of downstream oncogenes. Most clear cell renal cell carcinoma (ccRCC) tumors are associated with VHL deletion or inactivation resulting in HIF-2α overexpression that represents a key contributor to tumorigenesis, thereby making belzutifan a uniquely optimal drug for targeting ccRCC. …”
Get full text

Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model by Panadda Yotsomnuk, Amarnath Praphakar Rajendran, Daniel Nisakar Meenakshi Sundaram, Luis Carlos Morales, Cezary Kucharski, Mohammad Nasrullah, Wanwisa Skolpap, Xiaoyan Jiang, Spencer B. Gibson, Joseph Brandwein, Hasan Uludağ

“…The siRNAs utilized in this study were targeting the oncogenes FLT3 and KMT2A::MLLT3. Both lipopolymers gave similar-size siRNA complexes (210–220 nm) with positive <i>ζ</i>-potentials (+17 to +25 mV). …”
Get full text

Synchronous primary aneurysmal bone cysts: A rare case report and literature review by Noori Al Kadhim, DO, Akinyemi A Akintayo, MD, Alexander Ree, MD, Pedram Rezai, MD

“…They have characteristic imaging and histologic features and have historically been classified into two types: primary ABCs, which are true neoplasms linked to specific oncogenes, and secondary ABCs, which are preceded by other bone lesions. …”
Get full text

Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma? by Daniela Göppner, Martin Leverkus

“…The discovery of specific, causal mutations such as BRAF or KIT oncogenes not only renders a targeted and thus more effective therapeutic approach possible, but also gives rise to a new genetic-based classification. …”
Get full text

Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus by Maofei Zhu, Maofei Zhu, Yueming Chu, Yueming Chu, Qiang Yuan, Qiang Yuan, Junfeng Li, Silin Chen, Lin Li, Lin Li, Lin Li

“…Then, up- and down-regulated genes were intersected with the oncogenes and the tumor suppressor genes respectively, to obtain the differentially expressed onco/tumor suppressor genes in SCCE. …”
Get full text

Crystal Structures of Tcl1 Family Oncoproteins and Their Conserved Surface Features by John M. Petock, Ivan Y. Torshin, Yuan-Fang Wang, Garrett C. Du Bois, Carlo M. Croce, Robert W. Harrison, Irene T. Weber

“…Members of the TCL1 family of oncogenes are abnormally expressed in mature T-cell leukemias and B-cell lymphomas. …”
Get full text

Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes by Saloni Mangal, Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Rajesh Kumar Singh, Jahanvi Sanchitra, S.K. Asif Jan, Pratibha Pandey, Bimlesh Kumar, Anil Kumar Singh

“…Genetic mutations, chromosomal abnormalities, transcription factors, mutations in tumor suppressor genes, and mutations in oncogenes have all been associated with an increased risk of LC development. …”
Get full text

Impact of the crosstalk between the PTEN and PAFR as well as PAFR and EGFR pathways in cancer by Anita Thyagarajan, Zaid Sirhan, Ravi P. Sahu

“…While the activation of oncogenes fuels cancer progression and escape mechanisms, tumor suppressors regulate and counterbalance the negative effects of oncogenic signaling. …”
Get full text

TNPO1-Mediated Nuclear Import of FUBP1 Contributes to Tumor Immune Evasion by Increasing NRP1 Expression in Cervical Cancer by BiKang Yang, Jing Chen, YinCheng Teng

“…Far upstream element binding protein 1 (FUBP1), a DNA-binding protein, participates in diverse tumor-promoting behaviors by regulating the expression of oncogenes in the nucleus, but the underlying mechanisms remain to be elucidated. …”
Get full text

The role of circadian rhythm regulator PERs in oxidative stress, immunity, and cancer development by Baimei Zhao, Eugenie Nepovimova, Qinghua Wu

“…Crucially, PERs modulate cancer cell behaviors including proliferation, apoptosis, and migration by influencing the levels of cell cycle proteins and stimulating the expression of oncogenes c-Myc and MDM2. PER2/3, as antagonists in cancer stem cell biology, play important roles in differentiating cancer stem cells and in maintaining their stemness. …”
Get full text

p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. by Karen S Kelly-Spratt, Kay E Gurley, Yutaka Yasui, Christopher J Kemp

“…Ectopic expression of oncogenes such as Ras induces expression of p19(Arf), which, in turn, activates p53 and growth arrest. …”
Get full text

PAI-1 Expression Is Required for HDACi-Induced Proliferative Arrest in ras-Transformed Renal Epithelial Cells by Stephen P. Higgins, Craig E. Higgins, Paul J. Higgins

“…Malignant transformation of mammalian cells with ras family oncogenes results in dramatic changes in cellular architecture and growth traits. …”
Get full text

The Immune Response to Tumors as a Tool toward Immunotherapy by F. Pandolfi, R. Cianci, D. Pagliari, F. Casciano, C. Bagalà, A. Astone, R. Landolfi, C. Barone

“…Finally, monoclonal antibodies may be used to target oncogenes.…”
Get full text

The role of ESRP1 in solid tumor development through the regulation of CD44 splicing and EMT processes by Lili Wang, Min Zhang, Lei Ke Zhao, Xiaohan Yuan, Houyu Zhao, Yanting Liu, Yinghua Ji, Ping Lu

“…The field of cancer research is increasingly focusing on the role of tumor-related oncogenes and heterogeneous proteins in the development of cancer. …”
Get full text

CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells by Kiel T. Tietz, Braedan M. McCluskey, Conor R. Miller, Yingming Li, Sarah A. Munro, Scott M. Dehm

“…Altered alternative polyadenylation occurs in numerous cancers and can downregulate tumor-suppressor genes and upregulate oncogenes. We found that the cleavage and polyadenylation specificity factor (CPSF) complex factor CPSF1 is upregulated in patients with advanced prostate cancer, with high CPSF1 expression correlating with worse progression-free survival. …”
Get full text

FGFRL1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling by Haiyan Tai, Zhiyong Wu, Su’an Sun, Zhigang Zhang, Congjian Xu

Get full text